Seroconversion following anal and genital HPV infection in men: The HIM study  by Giuliano, Anna R. et al.
Seroconversion following anal and genital HPV infection in men:
The HIM study
Anna R. Giuliano a,n, Raphael Viscidi b, B. Nelson Torres a, Donna J. Ingles a,
Staci L. Sudenga a, Luisa L. Villa c, Maria Luiza Baggio d, Martha Abrahamsen a,
Manuel Quiterio e, Jorge Salmeron e,f, Eduardo Lazcano-Ponce e
a Center for Infection Research in Cancer, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL, USA
b School of Medicine, Johns Hopkins University, Baltimore, MD, USA
c School of Medicine, University of São Paulo, São Paulo, Brazil
d Center of Translational Research in Oncology, ICESP, São Paulo, Brazil
e Instituto Nacional de Salud Pública, Cuernavaca, Mexico
f Instituto Mexicano del Seguro Social, Cuernavaca, Mexico
a r t i c l e i n f o
Article history:
Received 12 May 2015
Received in revised form
17 June 2015
Accepted 18 June 2015
Available online 30 June 2015
Keywords:
HPV
Men
Seroconversion
HPV antibodies
Human papillomavirus
a b s t r a c t
Background: Protection from naturally acquired human papillomavirus (HPV) antibodies may inﬂuence
HPV infection across the lifespan. This study describes seroconversion rates following genital, anal, and
oral HPV 6/11/16/18 infections in men and examines differences by HPV type and anatomic site.
Methods: Men with HPV 6/11/16/18 infections who were seronegative for those genotypes at the time of
DNA detection were selected from the HPV Infection in Men (HIM) Study. Sera specimens collected r36
months after detection were analyzed for HPV 6/11/16/18 antibodies using a virus-like particle-based
ELISA. Time to seroconversion was separately assessed for each anatomic site, stratiﬁed by HPV type.
Results: Seroconversion to Z1 HPV type (6/11/16/18) in this sub-cohort (N¼384) varied by anatomic
site, with 6.3%, 18.9%, and 0.0% seroconverting following anal, genital, and oral HPV infection,
respectively. Regardless of anatomic site, seroconversion was highest for HPV 6 (19.3%). Overall,
seroconversion was highest following anal HPV 6 infection (69.2%). HPV persistence was the only factor
found to inﬂuence seroconversion.
Conclusions: Low seroconversion rates following HPV infection leave men susceptible to recurrent
infections that can progress to HPV-related cancers. This emphasizes the need for HPV vaccination in
men to ensure immune protection against new HPV infections and subsequent disease.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Human papillomavirus (HPV) infection is the cause of multiple
cancers in both men and women [1]. The rate of HPV acquisition
appears to differ by gender and by anatomic site of infection [2]. A
high prevalence of genital HPV has been observed in men across the
lifespan, with the rate of new genital HPV acquisition remaining
constant in menwith age [3]. This age pattern is signiﬁcantly different
thanwhat has been observed in women, where rates of new infection
decrease with age [4,5]. Similarly, anal HPV prevalence in men appears
constant across the lifespan [6,7], and oral HPV prevalence may
actually increase with age in men [8–10]. The factors that underlie
the association between age and HPV infection at multiple anatomic
sites in men remain unknown. Differences in sexual behavior across
the lifespan of men and women may contribute to differences in HPV
prevalence observed between the sexes by age. A proportion of newly
detected infections may also be due to reactivation of a latent infection
or ﬂuctuations in the level of viral replication in individuals with a
persistent infection. Another factor that may inﬂuence HPV prevalence
across the lifespan is protection conferred from naturally acquired
HPV antibodies.
HPV seroprevalence studies have consistently demonstrated that a
smaller proportion of heterosexual men are HPV seropositive com-
pared to men who have sex with men (MSM) or to women [11]. In
addition, the anatomic site of HPV infection may inﬂuence immune
response, as infection at mucosal epithelia such as the cervix and anal
canal may induce stronger immune responses compared to infection
at keratinized epithelia such as the genital skin [12–14]. To date, few
studies have examined the proportion of men who seroconvert
following HPV infection and the rate at which men seroconvert
following natural HPV infection at the genitals [15,16]. Only one study
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examined the rate of seroconversion following infection at multiple
anatomic sites [16], but this study was conducted among a highly
select group of men who have sex with men (MSM), some of whom
were HIV-positive, factors known to inﬂuence HPV infection and
antibody status [17,18].
The purpose of this study was to describe the rate of serocon-
version following HPV infection at the anal canal, oral epithelium,
and genitals in men ages 18–70 years participating in the HPV
Infection in Men (HIM) Study and to examine differences in anti-
body response by HPV type and anatomic site of infection.
Materials and methods
Men were recruited in São Paulo, Brazil, Cuernavaca, Mexico, and
Tampa, Florida from June 2005 to September 2009 for the prospective
HIM Study. Inclusion criteria included an age of 18–70 years, no plans
to relocate during the four year study, no self-reported history of
penile or anal cancer or genital warts, and no current sexually
transmitted infections (STIs), including HIV. Additional details of the
study design have been described previously [3,9]. The Human
Subjects Committees of the University of South Florida (Tampa, FL,
USA), Ludwig Institute for Cancer Research (São Paulo, Brazil), Centro
de Referência e Treinamento em Doenças Sexualmente Transmissíveis
e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Pública de
México (Cuernavaca, Mexico) approved all study procedures (IRB
approval numbers 102660 [U.S.], 028/2004 [Brazil], and CI440 [Mex-
ico]). All participants provided written informed consent.
Study protocol
A total of 4123 men enrolled in the HIM Study. Follow-up occurred
at six-month intervals for a total of four years. A total of 72 men
acknowledged HIV infection after enrollment and were removed from
further analysis. Of the remaining 4051 men, 3661 (90.4%) men
returned for at least the ﬁrst six-month follow-up visit.
Participants completed an 88-item computer-assisted self-
interview (CASI) at each visit, written in the region’s primary language
(Portuguese, Spanish, or English). The validated CASI questionnaire
elicited information about participant demographics, substance use,
and sexual behaviors [19].
At each study visit, a clinician examined participants for STI
symptoms, including anogenital warts and lesions, and genital, anal,
and oral specimens were obtained. For genital HPV sampling, the
clinician used a saline-wetted swab to sweep 3601 around the coronal
sulcus and glans penis, and if present, a retracted prepuce. A second
swabwas used to sample the entire surface of the penile shaft, while a
third was used to sample the scrotum. Finally, the clinician used a
separate swab to sample the anal canal. Each swabwas placed in a vial
of transport media (STM, Qiagen) and stored at –80 1C. For detection
of genital HPV, swabs from the coronal sulcus/glans, shaft, and
scrotum were combined. Oral gargle specimens were collected by a
30-s rinse/gargle with 15 mL of locally available mouthwash and
processed as previously published by our group and others [9,10]. All
specimens were stored at –80 1C until PCR analyses and genotyping
were conducted.
At each study visit, study staff drew 10 mL of blood. Blood was
processed at the clinic site and later aliquoted into cryovials and
placed in a –20 1C freezer pending transfer to long-term storage at
–80 1C. Sera were sent on dry ice to Johns Hopkins University for
HPV antibody testing. Enrollment serostatus of the HIM Study
cohort has been previously reported [20].
HPV DNA analyses
DNA was extracted from specimens using the QIAamp DNA Mini
Kit (Qiagen) and underwent PCR and HPV genotyping as previously
described using the Linear Array method (Roche Diagnostics)
[3,13,20–22] to detect 37 genital HPV types: 6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 42, 45, 5156, 58, 59, 61, 62, 64, 6673, 8184, IS39, and
CP6108 [21]. Accuracy and potential contamination were assessed
using non-template negative controls and CaSki DNA-positive con-
trols. β-globin positivity at enrollment and all follow-up visits was
greater than 97%. Specimens that were negative for β-globin and all
HPV types were considered invalid and were excluded from this
analysis.
Seroconversion study population
Participants selected for inclusion in this analysis of HPV serocon-
version: (1) had HPV 6, 11, 16, or 18 DNA detected at the genital, anal,
or oral site; (2) were seronegative for HPV 6, 11, 16, or 18 at the visit at
which the relevant type-speciﬁc HPV DNA detection occurred and up
to two visits prior; and, (3) had no prior detection of the same HPV
type at the other two anatomic sites.
Archived serum specimens for HPV antibody analyses were avail-
able for all men in the seroconversion sub-cohort. To ensure attribu-
tion of the antibody response to infection at a speciﬁc anatomic site,
menwith prior detection of a speciﬁc HPV type at a different anatomic
site were removed from analyses for the anatomic site under cons-
ideration. For example, a man with HPV 6 DNA detected ﬁrst at the
genitals and later at the anal canal was included in the genital
seroconversion analysis but not the anal seroconversion analysis.
Men with concurrent same type HPV infection at multiple anatomic
sites were excluded from this analysis. As a single participant could
have infections with multiple HPV types, there were more infections
than men included in this analysis.
HPV antibody testing
HPV serum samples collected at the time of HPV DNA detection,
up to 12 months prior to HPV detection, and at subsequent six-month
intervals for up to 36 months post-DNA detection were evaluated for
the presence of HPV antibodies to HPV 6, 11, 16, and 18 – the types
that cause a majority of HPV-related disease in men – using a
previously described type-speciﬁc method [14,20]. Brieﬂy, serum
antibodies to these four HPV types were individually measured using
a virus-like particle (VLP)-based ELISA. Serum samples were tested
using a single lot of reagents. To further ensure reliability of results,
specimens were tested in duplicate on separate plates, with results
from retesting of specimens exceeding a preset coefﬁcient of variation.
To minimize inter-assay variation, serial samples from the same
subject were tested on the same day. Cutoff values for seropositivity
were determined using optical density (OD) values greater than the
mean OD value plus ﬁve standard deviations (SDs) and were 0.3, 0.3,
0.2, and 0.2 for HPV 6, 11, 16, and 18, respectively. Antibody titers
below these values were not classiﬁed as seroconverters. Means and
SDs were estimated using serum samples from children 1 to 10 years
of age after exclusion of outliers. Quality control was assured through
preparation of positive and negative controls in each of the serology
assays.
Statistical analysis
Selected baseline characteristics, including age, circumcision status,
smoking status, and sexual orientation, were compared between
those who did and did not seroconvert using the Chi Square exact
and Wilcoxon rank sum tests. The time-to-event approach was
applied to assess the time from type-speciﬁc infection at one of three
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anatomic sites to seroconversion to the same HPV type that was
detected using the KaplanMeier method. Infections that did not
result in seroconversion were censored at the last visit. Time-to-event
analyses were stratiﬁed by HPV type (6, 11, 16, 18) at each anatomic
site. Viral infection was categorized as transient (one-time HPV DNA
detection) or persistent (HPV DNA detected at two or more con-
secutive visits, spaced 6 months apart). To investigate potential
heterogeneity by country, age group, sexual orientation, circumcision,
and viral persistence (transient HPV DNA detection vs. infections
persisting for Z6 months), stratiﬁed KaplanMeier curves were
estimated for HPV 16 and HPV 6, the HPV types with sufﬁcient events
to support these analyses. The log-rank test was used to compare the
probability of seroconversion between groups. Data were analyzed
using SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
A total of 384 men with HPV 6, 11, 16, or 18 infections at the
genital, anal canal, or oral cavity qualiﬁed for the HIM Study serocon-
version sub-cohort, with their characteristics presented in Table 1. No
statistically signiﬁcant differences were noted between participants
who seroconverted to at least one HPV type (n¼35) following an HPV
infection compared to men who did not seroconvert (n¼349)
(Table 1). However, the mean age of men who seroconverted follow-
ing HPV 16 infection was marginally lower compared to those who
did not (27.0 vs. 32.6 years, p¼0.059) (data not shown). Among men
with anal HPV infections, 33% (16/48) were classiﬁed as men who
have sex withmen (MSM) and 8.3% (4/48) were classiﬁed as menwho
have sex with women and men (MSWM).
The majority of HPV infections detected at the oral site were
preceded by an infection with the same HPV type at either the
genital or anal anatomic sites. As genital HPV prevalence is known
to be higher than prevalence observed at the anal canal or oral
epithelium,[2] among this cohort of predominantly heterosexual
men, genital infections predictably comprised the largest sample
(n¼399), followed by anal infections (n¼53) and oral infections
(n¼3). An interesting question we attempted to address was
whether seroconversion differed among men who had the same
HPV type concurrently at multiple anatomic sites compared to one
anatomic site only. Only 16 participants had HPV DNA detected
simultaneously at the genitals and anal canal, none of whom
seroconverted to that HPV type (data not shown).
Overall, 24-month seroconversion varied by anatomic site of HPV
detection: 6.3%, 18.9%, and 0.0% seroconverted following infectionwith
any of the four HPV types (6, 11, 16, or 18) at the anal canal, genitals,
and oral epithelium, respectively (Table 2). All menwho seroconverted
following an anal HPV infection did so by month 12. Among menwho
seroconverted to HPV 6, 11, 16, or 18 within 24 months following a
genital HPV infection, 83.3%, 66.7%, 62.5%, and 50% seroconverted by
12 months. Regardless of anatomic site of infection, seroconversion
was highest among participants with HPV 6 (19.3%) and lowest
among those with HPV 16 (3.6%) or 18 (3.4%) infections. Seroconver-
sion was highest following HPV 6 infection at the anal canal (69.2%).
Among men who seroconverted to one or more HPV types, the
median time to seroconversion following any HPV DNA detection at
the genitals was 257 days (min, max¼163, 1003). Although prob-
ability of seroconversion following genital HPV DNA detection differed
by HPV type (po0.05), the median time to seroconversion did not
differ signiﬁcantly by HPV type (Fig. 1a). However, a shorter time to
seroconversion was noted for HPV types 6 and 11 (223 and 182 days
[7.4 and 6.1 months], respectively), compared to HPV types 16 and 18
(317 and 311 days [10.6 and 10.4 months], respectively).
At the anal canal, the median time to seroconversion following any
HPV DNA detection was 200 days (min, max¼181, 263). Similar to
seroconversion at the genitals, the median time to seroconversion
following an anal HPV 6 infection was 197 days (6.6 months). Median
time to seroconversion following an anal HPV 18 infection was 219
days [7.3 months] (Fig. 1b). Regardless of anatomic site of infection, a
shorter time to seroconversion following HPV 6 infection (197 days)
was observed compared to other HPV types (266 days). However,
these differences did not reach statistical signiﬁcance (p¼0.2).
Overall, seroconversion following genital or anal infection did not
differ by age, country of residence, race, circumcision status, smoking
status, or sexual orientation (data not shown). However, menwho had
persistent genital HPV 6 infection were more likely to seroconvert
compared to those with transient infections (Fig. 2a). Seroconversion
did not differ when men with transient and persistent genital HPV 16
infections were compared (Fig. 2b).
Amongmenwho seroconverted following genital HPV 6 infections,
men with infections persisting Z6 months also had a signiﬁcantly
(po0.005) more rapid rate of seroconversion (median time¼223
days) compared to men with transient HPV 6 genital infections
(median time¼586 days) (Fig. 2a). Viral persistence did not inﬂuence
median time to seroconversion following genital HPV type 11, 16, or 18
infections.
Discussion
In this multinational study of men ages 18–70 years, we demon-
strate a low rate of seroconversion following HPV infection, regardless
of anatomic site of infection. Overall, only 7.7% of men developed
detectable serum HPV antibodies. Type-speciﬁc HPV seroconversion
was higher and faster following HPV 6 infection (19.3%, regardless of
anatomic site) compared with HPV 11, 16, and 18 infections and was
highest following HPV 6 infection at the anal canal (69.2% serocon-
verted). In addition, persistent HPV 6 infection at the genitals was
more likely to result in seroconversion compared to transiently
detected infection.
We previously reported low HPV 6, 11, 16, and 18 seroprevalence
among men participating in the HIM Study cohort [20], an observation
consistent with reports from studies conducted in different world
regions with varying sexual behaviors and characteristics [11,17,18,22–
24]. Among studies that included both males and females, HPV
seroprevalence in men is consistently lower (typically twofold lower
for HPV 16) than that reported among women [11]. This lower HPV
seroprevalence, combined with the observation that genital HPV DNA
prevalence is high and remains relatively constant across the lifespan
of men [3], has led to the hypothesis that seroconversion following
HPV infection in men is lower than that reported among women.
However, prior reports of higher HPV seroprevalence among MSM
andmenwith anal HPV infections compared with genital infections in
cross-sectional analyses [14,17,24] suggested that the immune
response to HPV in men may differ by anatomic site of infection.
As suspected, the percentage of men who seroconverted following
HPV infection was low, approximately four- to tenfold lower than that
observed among women following cervical infection [25]. For exam-
ple, in the current study, 4.1% of men seroconverted following genital
HPV 16 detection compared to 60% of women following cervical HPV
16 detection [25], regardless of whether the infection was persistent
or transient. Two other studies have examined seroconversion follow-
ing genital HPV infection in men, both documenting similarly low
rates. Among young university male students, 13.0% seroconverted
within 24 months following genital HPV 16 infection [15]. In a study of
MSM recruited from infectious disease and STI clinics in Amsterdam,
8.2% of HIV-negative and 12.4% of HIV-positive men seroconverted
within 12 months following HPV 16 detection [16]. This low antibody
response to genital HPV infections in men may partially explain the
observation of recurrent HPV infectionwith the same type in men and
the constant prevalence and incidence rates across the lifespan [3].
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Differences in the immune response to HPV were observed by
HPV type, similar to prior reports that focused on high-risk HPV
types [15,24]. However, to our knowledge, the current study is the
only to examine seroconversion to low-risk HPV types 6 and 11 in
men. Following HPV 6 infection at the genitals, 12.5% of men
seroconverted, compared with only 4.1% and 2.6% in response to
HPV 16 and 18 infections, respectively. In contrast, only slight
differences in seroconversion by HPV type were observed
Table 1
Characteristics of HIM Study seroconversion sub-cohort (N¼384) by seroconversion status to HPV types 6, 11, 16, or 18 within 36 months post HPV infection.
Entire cohort (N¼384) Seroconverteda (N¼35) No Seroconversion (N¼349)
Age, in years
Mean (SD) 32.8 (10) 33.1 (11) 32.7 (9.9)
Median (range) 31 (20–71) 32 (20–70) 31 (20–71)
Age, in years
18–30 187 (48.7) 17 (48.6) 170 (48.7)
31–44 149 (38.8) 14 (40) 135 (38.7)
45–70 48 (12.5) 4 (11.4) 44 (12.6)
Country
U.S. 148 (38.5) 13 (37.1) 135 (38.7)
Brazil 153 (39.8) 12 (34.3) 141 (40.4)
Mexico 83 (21.6) 10 (28.6) 73 (20.9)
Race
White 207 (53.9) 17 (48.6) 190 (54.4)
Black 70 (18.2) 6 (17.1) 64 (18.3)
Asian/Native American/ Native Alaskan 13 (3.4) 1 (2.9) 12 (3.4)
Mixed race 94 (24.5) 11 (31.4) 83 (23.8)
Education
r12 years 160 (41.7) 16 (45.7) 144 (41.3)
13–15 years 116 (30.2) 13 (37.1) 103 (29.5)
Z16 years 108 (28.1) 6 (17.1) 102 (29.2)
Marital status
Single/never married 208 (54.2) 17 (48.6) 191 (54.7)
Married 92 (24) 10 (28.6) 82 (23.5)
Cohabitating 49 (12.8) 6 (17.1) 43 (12.3)
Divorced/separated/widowed 35 (9.1) 2 (5.7) 33 (9.5)
Circumcision
None 203 (52.9) 17 (48.6) 186 (53.3)
Full 176 (45.8) 17 (48.6) 159 (45.6)
Partial 5 (1.3) 1 (2.9) 4 (1.1)
Smoking status
Current 98 (25.5) 10 (28.6) 88 (25.2)
Former 60 (15.6) 4 (11.4) 56 (16.0)
Never 226 (58.9) 21 (60.0) 205 (58.7)
Sexual orientationb
MSW 337 (87.8) 28 (80) 309 (88.5)
MSM 41 (10.7) 6 (17.1) 35 (10)
MSWM 6 (1.6) 1 (2.9) 5 (1.4)
Lifetime no. female partners
0–1 39 (10.2) 8 (22.9) 31 (8.9)
2–9 122 (31.8) 8 (22.9) 114 (32.7)
10–49 176 (45.8) 12 (34.3) 164 (47.0)
Z50 21 (5.5) 2 (5.7) 19 (5.4)
Refused 26 (6.8) 5 (14.3) 21 (6.0)
Lifetime no. male partners
0 305 (79.4) 24 (68.6) 281 (80.5)
1–9 44 (11.5) 5 (14.3) 39 (11.2)
Z10 17 (4.4) 1 (2.9) 16 (4.6)
Recentc no. female partners
0 92 (24.0) 10 (28.6) 82 (23.5)
1 139 (36.2) 14 (40.0) 125 (35.8)
2 57 (14.8) 1 (2.9) 56 (16.0)
Z3 83 (21.6) 7 (20.0) 76 (21.8)
Refused 13 (3.4) 3 (8.6) 10 (2.9)
Recentc no. male partners
0 344 (89.6) 28 (80.0) 316 (90.5)
Z1 25 (6.5) 4 (11.4) 21 (6.0)
Refused 15 (3.9) 3 (8.6) 12 (3.4)
a Includes all men who seroconverted to one or more of HPV types 6, 11, 16, or 18.
b MSW¼Men having sex with women; MSM¼men having sex with men; MSWM¼ men having sex with women and men.
c Within past six months. P values were derived using Monte Carlo estimation of the exact Pearson chi-squared test (for categorical variables) and the Wilcoxon test (for
continuous variables) and were not signiﬁcant (p40.05) for any variables.
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following cervical infection in women (60% and 69% following HPV
16 and 6 infections, respectively) [25]. Interestingly, while sero-
conversion following HPV 16 infection did not differ by anatomic
site of infection, seroconversion following HPV 6 infection at the
anal canal was signiﬁcantly higher than at the genitals (69.2%
compared to 12.5%), similar to the 69% reported among women
following cervical HPV 6 infection [25]. HPV 16 is known to evade
immunity and is more likely to persist compared to HPV 6 [26]. As
genital HPV 6 has a high rate of progression to condyloma (25%
of HPV 6 infections progress in men) [27], we examined whether
condyloma incidence might inﬂuence seroconversion following
genital HPV 6 infection. Although a slightly higher rate of ser-
oconversion was observed among men who developed HPV 6-
related condyloma, differences between groups did not reach
statistical signiﬁcance; 16% vs. 11.3% of men with and without
condyloma, respectively, seroconverted to HPV 6. To adequately
address whether seroconversion is higher subsequent to lesion
development, studies among a larger sample of men with HPV-
related anal and genital lesions need to be conducted. The low rate
of seroconversion among men may be due to a poor immune
response or may simply reﬂect that HPV detected is deposition
and not true infection in men. Regardless, our study and the other
two studies published among men have shown that circulating
antibodies to HPV do not confer protection against subsequent
HPV infection in men, in contrast to the partial protection
observed among females. [14,28,29].
Few factors inﬂuenced seroconversion and the rate at which men
seroconverted following HPV infection in the current study. We
examined rates of seroconversion for the four vaccine HPV types by
age, race, sexual orientation, circumcision, smoking status, and infec-
tion persistence. No demographic or behavioral factors evaluated were
associated with seroconversion. The only factor that inﬂuenced sero-
conversion was viral persistence, with a higher and faster rate of
seroconversion observed following persistent HPV 6 infection at the
genitals. Similar results have been reported among HIV-negative
MSM, in which a higher probability of seroconversion was observed
following anal infection but not penile infection [16]. Among
university-aged men, those who reported ever smoking and men
with HPV detected at multiple genital anatomic sites were at
signiﬁcantly higher risk of seroconversion [15]. Differences in popula-
tion characteristics likely contributed to differences in factors asso-
ciated with seroconversion across studies.
As with any epidemiologic study, there are limitations that need to
be considered when interpreting the ﬁndings. The low prevalence and
incidence of oral HPV infections [9] resulted in a small sample size to
evaluate seroconversion following oral HPV detection. Larger studies
and/or longer follow-up of existing male cohorts will be required to
adequately assess rates of seroconversion following oral HPV detec-
tion. Additionally, as only a subset of anal HPV genotyping data was
available for this study, we were unable to compare seroconversion
following transient vs. persistent anal HPV infection. It is also possible
that seroconversion would be different when examining recurrent
type-speciﬁc HPV infections or restricting to incident infections only,
and that by excluding information from subsequent infections, there is
a potential formisclassiﬁcation of seroconversion to the ﬁrst site of
HPV DNA detection. However, a major strength of our analysis is that
we evaluated menwith infections detected at the ﬁrst anatomic site of
detection in an attempt to evaluate differences in seroconversion by
anatomic site of infection. Other studies only evaluated seroconversion
at one anatomic site, regardless of whether infection ﬁrst occurred at
this anatomic site or at another [15]. In the only other publication that
examined HPV infection at multiple anatomic sites in men [16], it is
unclear how consecutive infections with the same HPV type at
different anatomic sites were analyzed. The current study also focused
only on the HPV types that cause the majority of disease in men (HPV
6, 11, 16, 18). While other HPV types are commonly detected in men,
Table 2
Percent of men who seroconverted within 36 months following HPV DNA detection
of an genital, anal, or oral infection with HPV 6, 11, 16, or 18.
HPV 6 n/N
(%)
HPV 11 n/N
(%)
HPV 16 n/N
(%)
HPV 18 n/N
(%)
Overalla n/N
(%)
All sitesb 21/109
(19.3)
3/35 (8.6) 8/223 (3.6) 3/88 (3.4) 35/455 (7.7)
Genital 12/96
(12.5)
3/33 (9.1) 8/193 (4.1) 2/77 (2.6) 25/399
(18.9)
Anal 9/13 (69.2) 0/2 (0.0) 0/27 (0.0) 1/11 (9.1) 10/53 (6.3)
Oral 0/0 (0.0) 0/0 (0.0) 0/3 (0.0) 0/0 (0.0) 0/3 (0.0)
n¼number of men per HPV type per anatomic site who seroconverted; N¼total
number of men per HPV type per anatomic site.
a HPV DNA-positive for HPV 6, 11, 16, or 18.
b Infection at genital, anal, or oral site.
Percent seroconversion by genital HPV type 
N % median time  (in days)
HPV6 12 12.5 223 
HPV11 3 9.1 182 
HPV16 8 4.2 317 
HPV18 2 2.6 311 
Percent seroconversion by anal HPV type 
N % median time  (in days)
HPV6 9 69.2 197 
HPV11 0 0  
HPV16 0 0  
HPV18 1 9.1 219 
Fig. 1. Time to seroconversion following: (a) genital or (b) anal infection with HPV
6, 11, 16, or 18.
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these rarely progress to disease in men [30]. To our knowledge, this is
the only study that examined seroconversion following HPV 6 and 11
infections in men, the types that cause 90% of genital warts.
Conclusions
In conclusion, low rates of seroconversion following HPV infection
in men, coupled with a lack of demonstrated protection against
infection among those that do seroconvert, may leave men susceptible
to recurrent infections, especially with HPV type 16, the cause of anal,
oropharyngeal, oral, and penile cancers in men. In contrast, nearly
100% seroconversion to all included types following HPV vaccination
has been documented in men. Thus, HPV vaccination is the only
reliable method to ensure immune protection against new HPV
infections and subsequent disease in males [18,31].
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